Media stories about Onconova Therapeutics (NASDAQ:ONTX) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Onconova Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.9142129534968 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
Several research firms have issued reports on ONTX. Zacks Investment Research raised Onconova Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Maxim Group set a $6.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 9th. Finally, HC Wainwright set a $6.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $7.33.
Onconova Therapeutics (NASDAQ ONTX) traded up $0.01 during midday trading on Monday, reaching $1.07. 75,600 shares of the company’s stock traded hands, compared to its average volume of 447,261. Onconova Therapeutics has a 12-month low of $0.95 and a 12-month high of $3.88. The stock has a market cap of $20.78, a PE ratio of -0.39 and a beta of 0.08.
In other news, major shareholder 683 Capital Management, Llc acquired 200,000 shares of the stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $1.04 per share, for a total transaction of $208,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 29.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Onconova Therapeutics (ONTX) Share Price” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/19/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-onconova-therapeutics-ontx-share-price.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.